US Broker Ratings

Altimmune, Inc. (ALT) Stock Analysis: Uncovering a 462.87% Potential Upside in Biotechnology

Altimmune, Inc. (NASDAQ: ALT) is making significant waves in the biotechnology sector with its groundbreaking work in developing therapies for serious liver diseases. This Gaithersburg, Maryland-based company is capturing investor..

RxSight, Inc. (RXST) Stock Analysis: Exploring a Potential 60% Upside for Investors

RxSight, Inc. (NASDAQ: RXST), a healthcare company specializing in medical devices, particularly those used in cataract surgery, is capturing investor attention with its innovative approach in enhancing postoperative visual acuity...

Castle Biosciences (CSTL): Investor Outlook Reveals 28% Potential Upside

Castle Biosciences, Inc. (NASDAQ: CSTL), a prominent player in the healthcare sector, is garnering attention from investors due to its innovative solutions in the diagnostics and research industry. Headquartered in..

Arbutus Biopharma Corporation (ABUS): Investor Outlook on Growth Potential and Analyst Ratings

Arbutus Biopharma Corporation (NASDAQ: ABUS) stands out in the biotechnology sector with its focus on developing novel therapeutics for infectious diseases, notably chronic Hepatitis B virus (HBV). As a clinical-stage..

AxoGen, Inc. (AXGN) Stock Analysis: Exploring a Potential 24% Upside in the Healthcare Sector

AxoGen, Inc. (NASDAQ: AXGN) has emerged as a compelling player in the healthcare sector, particularly in the medical devices industry. Specializing in peripheral nerve regeneration and repair, AxoGen’s innovative solutions..

Delcath Systems, Inc. (DCTH) Stock Analysis: Exploring 49% Potential Upside in the Medical Device Sector

Investors seeking opportunities in the healthcare sector may find Delcath Systems, Inc. (NASDAQ: DCTH) a compelling prospect. The company, which specializes in interventional oncology, primarily focuses on innovative treatments for..

REGENXBIO Inc. (RGNX) Stock Analysis: Unveiling a 227% Potential Upside in the Biotech Sector

REGENXBIO Inc. (NASDAQ: RGNX), a clinical-stage biotechnology company based in Rockville, Maryland, is garnering significant attention from investors due to its promising advancements in gene therapy and a remarkable potential..

STAAR Surgical Company (STAA)

⚠️ No article content returned.

..

Spyre Therapeutics, Inc. (SYRE): Analyst Ratings Point to a Potential 37.88% Upside in Biotech

In the competitive landscape of biotechnology, Spyre Therapeutics, Inc. (NASDAQ: SYRE) stands out not just for its cutting-edge research in inflammatory bowel and rheumatic diseases but also for the intriguing..

Dianthus Therapeutics, Inc. (DNTH) Stock Report: Analysts Predict a 55% Upside Potential

Dianthus Therapeutics, Inc. (DNTH) is making waves in the biotechnology industry with its promising pipeline of therapies aimed at severe autoimmune diseases. As a clinical-stage biotechnology company, Dianthus focuses on..

InMode Ltd. (INMD) Stock Analysis: Exploring a 13.93% Upside Potential in the Medical Devices Sector

InMode Ltd. (NASDAQ: INMD), a prominent player in the healthcare sector with a focus on medical devices, offers a compelling opportunity for investors seeking exposure to the burgeoning field of..

Vir Biotechnology, Inc. (VIR) Stock Analysis: A 93.82% Upside Potential Amidst Robust Revenue Growth

Vir Biotechnology, Inc. (NASDAQ: VIR), a prominent player in the biotechnology sector, has captured investor attention with a substantial upside potential of 93.82%. This clinical-stage biopharmaceutical company, headquartered in San..

Eton Pharmaceuticals, Inc. (ETON) Stock Report: Eyeing a 19.35% Upside with Robust Revenue Growth

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) stands out in the healthcare sector, specifically within the niche of specialty and generic drug manufacturing. With a current market cap of $1.7 billion, Eton..

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Navigating the Biotech Frontier with Strong Revenue Growth

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is making waves in the biotechnology sector, a space known for its volatility but also its potential for groundbreaking advancements. With a market capitalization of..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating Growth in the Biotechnology Sector

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a prominent player in the biotechnology industry, is capturing investor attention with its strategic focus on enabling the development of cutting-edge drug therapies, vaccines,..

CareDx, Inc. (CDNA) Stock Analysis: A Promising Player in Transplant Diagnostics with Strong Revenue Growth

CareDx, Inc. (NASDAQ: CDNA) stands at the forefront of the healthcare sector, specializing in diagnostics and research with a focus on improving outcomes for transplant patients. As of its latest..

Neuropace, Inc. (NPCE) Stock Analysis: A Promising Upside of 43% Amidst Healthcare Innovation

Neuropace, Inc. (NASDAQ: NPCE) stands at a pivotal point in the healthcare sector with its innovative approach to treating drug-resistant focal epilepsy. As a key player in the medical devices..

uniQure N.V. (QURE) Stock Analysis: Potential Upside Beckons Despite Recent Volatility

Investors keeping a close watch on uniQure N.V. (NASDAQ: QURE) are presented with an intriguing investment opportunity in the biotechnology sector, particularly given the company’s focus on gene therapy for..

Keros Therapeutics, Inc. (KROS) Stock Analysis: Biotechnology Innovator with 71% Potential Upside

Keros Therapeutics, Inc. (NASDAQ: KROS) is making waves in the biotechnology sector, capturing the attention of investors with its promising pipeline and significant potential upside. Headquartered in Lexington, Massachusetts, this..

CeriBell, Inc. (CBLL) Stock Analysis: Exploring a 17.55% Potential Upside Amid Robust Revenue Growth

CeriBell, Inc. (CBLL), a healthcare company specializing in medical devices, is capturing investor attention with its innovative EEG platform and a promising growth trajectory. Headquartered in Sunnyvale, California, CeriBell is..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds